Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | YAP1 | P46937 | 1/20 | 0.34 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870186 | 0.79 | ALDH1A1 (0.37) | ALDH1A1NPC1L3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL12436953 | 0.77 | EPHX2 (0.50) | ALDH1A1NPC1GAA | |
| SCHEMBL12436034 | 0.77 | ALDH1A1 (0.42) | ALDH1A1NPC1L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL15369211 | 0.76 | ALDH1A1 (0.41) | ALDH1A1NPC1L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL14902198 | 0.76 | ALDH1A1 (0.41) | ALDH1A1NPC1L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL17812266 | 0.76 | CPN1 (0.47) | ALDH1A1NPC1L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL13804082 | 0.76 | ALDH1A1 (0.41) | ALDH1A1NPC1L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL295163 | 0.74 | ALDH1A1 (0.50) | ALDH1A1NPC1L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL13629807 | 0.74 | ALDH1A1 (0.40) | ALDH1A1NPC1L3MBTL1GAASMN1; SMN2 | |
| SCHEMBL12436973 | 0.74 | NAMPT (0.53) | ALDH1A1NPC1L3MBTL1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | ALDH1A1 3648/4885NPC1 1587/4885L3MBTL1 1003/4885 |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | ALDH1A1 2667/4885NPC1 1263/4885L3MBTL1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.